MARCH | Sowing seeds for success
Spring hasn't quite yet sprung, but this time of year has people feeling hopeful. It's a time that ushers in a sense of renewal, optimism and rebirth. In business, spring is a good time to not only set some new goals for the upcoming quarter but also to reflect on the initial months of the year and the seeds that have been sown. Has what you planted started to sprout?
At Bruder Consulting & Venture Group (BCVG), we know what it's like to take a business from a humble seedling and nurture it to full bloom -- and we're here to be of strategic support. Our knowledgeable, innovative team of experts has years of experience helping Client Partners build and grow at any stage of business. We are representing several Orthobiologic companies and assets for sale or partnership in 2023 and happy to meet with potential buyers or partners interested in the following areas: Knee osteoarthritis, Intervertebral disc repair and regeneration, Musculoskeletal and wound care allografts, Cartilage defect repair, Biomaterials for Sports Medicine.
To learn more about how BCVG can drive value for your business, please visit our website and follow us on LinkedIn. Plus, if you know someone who would benefit from this information, please forward this newsletter to them or invite them to subscribe via the BCVG website. We’d love to start a conversation with you about the many ways we can work together.
|
|
|
CONFERENCE & LECTURE RECAP
BCVG founder Dr. Scott Bruder delivered a lecture at the annual Interventional Orthobiologics Foundation Max Experience conference in Phoenix in February.
For those who missed it, videos of the sessions are available at interventionalorthobiologics.org. One highlight of the event was a Town Hall with Dr. Bruder and Dr. Chris Centeno; they discussed FDA, FTC and OIG compliance and answered questions from the audience on how to avoid serious trouble.
|
|
INDUSTRY NEWS & EVENTS
COMING SOON FROM AAOS: Dr. Bruder is the lead editor, along with Dr. Roy Aaron, of the new book "Orthobiologics: Scientific and Clinical Solutions for Orthopaedic Surgeons." It will be available at the annual AAOS meeting in March at the Wolters Kluwer and AAOS booths, and it can be preordered now via the WK/AAOS online store, where members receive a 25% discount and free shipping.
AAOS MEETING: It's time to register for the AAOS meeting, to be held March 7-11 in Las Vegas. The BCVG team, including Dr. Bruder, Vice President Jim Petricek and Vice President Dr. Susan Drapeau, will be there and available for meetings to discuss product development and/or M&A needs. Dr. Bruder also will be teaching several courses, including: “Symposium - AAOS and Biologics Alliance Present: Use of Orthobiologics in Your Practice” (March 7), “Instructional Course Lecture - Orthobiologics Use and Marketing: FDA, FTC and Ethical Compliance” with Dr. Joanne Halbrecht (March 10) and “Update on Regulatory Status: How to Stay Out of Trouble” (March 10). Contact Dr. Bruder, Dr. Drapeau or Mr. Petricek to schedule a meeting, or reserve a Zoom meeting with Dr. Bruder.
|
|
TEAM NEWS: Meet Laura Rose, PhD
Laura Rose, PhD, is a biomedical engineer who joins BCVG as an Engagement Partner in Regulatory Affairs Strategy and Submissions after nearly 8 years at FDA.
She brings a comprehensive understanding of FDA regulations, guidance and decision-making, as well as a wealth of knowledge about regulation of devices and combination products for tissue engineering and regenerative medicine.
Laura served as the Assistant Director for the Division of Restorative, Repair and Trauma Devices in CDRH’s Office of Orthopedic Devices, where she led a large and diverse team of engineers, clinicians and scientists. Although she has interacted with all corners of FDA, she worked most extensively with CBER and CDER on orthopedic combination products and is known for her calm and thoughtful approach to regulatory problem solving. Prior to joining FDA, Laura served as a co-investigator on a cell-therapy IND as a Post-Doctoral Fellow at Johns Hopkins University. Laura earned her BSc in Biochemistry from the University of British Columbia (UBC) in Vancouver, Canada, and her PhD in Biomedical Engineering from the University of Alberta in Edmonton, Canada.
|
|
Here's what our Client Partners are saying ...
MaxBioPharma recently partnered with BCVG to lead the development of its FDA regulatory strategy and nonclinical safety plan. BCVG is preparing FDA submission materials and will oversee engagement and negotiations with the Agency.
“These efforts will greatly accelerate our pathway to bring Oxy133, our novel osteoinductive oxysterol, to market.”
-- Farhad Parhami, Founder, President & CEO, MaxBioPharma
|
|
|
|
|
|
